Pharmafile Logo

Beat inflation with virtual meetings and programs

At the time of writing, the average inflation rate worldwide sits at 7.4%, the highest it’s been for decades. Here in Canada, the inflation rate is not forecasted to come back down to “normal” levels until 2024. As a life science service provider working with companies across the world, we are seeing firsthand how some companies are already tightening their budgets in response to the ongoing economic uncertainty and other world events such as the war in Ukraine.

Inflation is impacting all aspects of in-person meetings

After 2+ years of COVID-19-imposed restrictions, many teams are itching to get back to in-person meetings. However, with flightgasoline, and food prices skyrocketing lately, in-person engagements are becoming more expensive and may not be the best “bang for your buck.” (That is, if your advisors and team members can even make it to the meeting on time amidst record flight cancellations and delays.)

The good news is that there are ways to beat inflation and still continue those vital engagements with your key stakeholders. Instead of relying only or mainly on in-person meetings for your advisory boardslearning programsco-author working groups, and internal corporate events, consider replacing some of these with inflation-neutral virtual engagements. Your customers’ needs have not gone away just because prices are up. If anything, it is more crucial than ever to gather insights from healthcare providers, payers, and patients on current market conditions

Read the rest of the article here to learn more!

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive...

No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the...

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.